NCT00596648 2026-01-13
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Exelixis
Phase 1/2 Completed
Clinical Trials
131 trialsNCT02296125 2026-01-09
FLAURA
AstraZeneca
Phase 3 Completed
NCT07271446 2025-12-09
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Precision Biotech Taiwan Corp.
Phase 1 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT01186861 2025-11-18
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Astellas Pharma Inc
Phase 2 Completed
NCT01221077 2025-11-18
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Astellas Pharma Inc
Phase 2 Completed
NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02424617 2025-02-26
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
BerGenBio ASA
Phase 1/2 Completed
NCT01010945 2024-11-21
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT00739453 2024-11-20
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma Inc
Phase 1 Completed
NCT02057380 2024-11-20
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Phase 2 Completed
NCT02352948 2024-07-26
ARCTIC
AstraZeneca
Phase 3 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT01104155 2023-06-22
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 2 Completed
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT01211483 2021-06-16
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT01199068 2021-05-13
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00606502 2021-03-05
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00130728 2021-01-14
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 3 Completed
NCT00456833 2020-12-21
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
Novartis
Phase 1 Completed
NCT01101334 2020-06-16
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Completed
NCT02013219 2020-04-21
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 1 Completed
NCT01667562 2019-12-20
ESSENCE
Hoffmann-La Roche
Phase 3 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01545947 2019-11-12
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT01900652 2019-09-18
Chime
Eli Lilly and Company
Phase 2 Completed
NCT01523587 2019-02-15
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT01801111 2018-11-02
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
Phase 1/2 Completed
NCT01260181 2018-10-31
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Hoffmann-La Roche
Phase 2 Completed
NCT01174563 2018-09-17
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
Hoffmann-La Roche
Phase 2 Completed
NCT01310036 2018-09-12
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
Hoffmann-La Roche
Phase 2 Completed
NCT01782690 2018-07-23
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Completed
NCT01395758 2018-04-03
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT00072631 2018-02-08
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT00139620 2018-02-08
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Astellas Pharma Inc
Phase 1 Completed
NCT00364351 2018-01-25
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Sanofi
Phase 3 Completed
NCT01378962 2018-01-23
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
Hoffmann-La Roche
Phase 2 Completed
NCT00033241 2018-01-10
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT00036647 2018-01-10
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Astellas Pharma Inc
Phase 3 Completed
NCT00040183 2018-01-10
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Astellas Pharma Inc
Phase 3 Completed
NCT01472016 2017-11-21
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01009073 2017-11-20
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie
Phase 1 Completed
NCT00619424 2017-11-17
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT01351415 2017-09-18
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 3 Completed